Provention Bio, Inc. (PRVB) financial statements (2022 and earlier)

Company profile

Business Address 55 BROAD STREET, 2ND FLOOR
RED BANK, NJ 07701
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments95,111121,82485,37358,539
Cash and cash equivalents78,190102,29439,16558,539
Short-term investments16,92119,53046,208 
Other undisclosed current assets5,9854,730  
Total current assets:101,096126,55485,37358,539
Noncurrent Assets
Operating lease, right-of-use asset373408 
Property, plant and equipment2,0111,437  
Long-term investments and receivables32,021   
Long-term investments32,021   
Other noncurrent assets120120  
Total noncurrent assets:34,5251,965  
Other undisclosed assets  6232,990
TOTAL ASSETS:135,621128,51985,99661,529
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities17,19216,7303,8401,871
Accounts payable3,5467,5681,775568
Accrued liabilities13,6469,1622,0651,303
Deferred revenue5,599  
Total current liabilities:22,79116,7303,8401,871
Noncurrent Liabilities
Long-term debt and lease obligation590715  
Operating lease, liability590715 
Liabilities, other than long-term debt1,506   
Deferred revenue1,506  
Other undisclosed noncurrent liabilities (715)  
Total noncurrent liabilities:2,096715  
Total liabilities:24,88717,4453,8401,871
Stockholders' equity
Stockholders' equity attributable to parent110,734111,07482,15659,658
Common stock6654
Additional paid in capital402,941288,725161,21295,430
Accumulated other comprehensive loss(139)(15)  
Accumulated deficit(292,074)(177,642)(79,061)(35,776)
Total stockholders' equity:110,734111,07482,15659,658
TOTAL LIABILITIES AND EQUITY:135,621128,51985,99661,529

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues1,395   
Gross profit:1,395   
Operating expenses(116,973)(99,687)(44,372)(26,814)
Operating loss:(115,578)(99,687)(44,372)(26,814)
Nonoperating income
(Investment Income, Nonoperating)
  1,087 
Loss from continuing operations before equity method investments, income taxes:(115,578)(99,687)(43,285)(26,814)
Other undisclosed income from continuing operations before income taxes146583 149
Loss from continuing operations before income taxes:(115,432)(99,104)(43,285)(26,665)
Income tax benefit1,000523 187
Net loss attributable to parent:(114,432)(98,581)(43,285)(26,478)
Preferred stock dividends and other adjustments   (276)
Net loss available to common stockholders, diluted:(114,432)(98,581)(43,285)(26,754)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(114,432)(98,581)(43,285)(26,478)
Other comprehensive loss(124)(15)  
Comprehensive loss, net of tax, attributable to parent:(114,556)(98,596)(43,285)(26,478)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: